Trilipix
(choline fenofibrate)ApprovedSmall molecule
AbbVieTrilipix is one of 44 small molecule programs targeting Atherosclerosis. It is currently in Approved.
1
Indications
3
Total Trials
1
Active Trials
43
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
54 competitors in Atherosclerosis
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Niacor
AbbVieApproved
Crestor
AstraZenecaApproved
Praluent
RegeneronApproved
Plavix
SanofiApproved
Aldactone
PfizerApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Selzentry
GSKApproved
Actos
TakedaApproved
Brilinta
AstraZenecaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Dec 15, 2008
TRILIPIX
NDA NDA022224
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for choline fenofibrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]